Healthcare / Medical DevicesBSE
$36.21
-1.90 (-4.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-78.4M · quality 67.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$23.7B
P/E
61.4x
↑EV/EBITDA
42.3x
↑ROE
0.4%
↑Gross Margin
17.3%
↓Debt/Equity
0.25
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-83.8%
FCF / Net income
-76.77x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.11B · net income $12.1M · FCF $-927.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.11B | $1.11B | $209.8M | $1.8M | — |
| Net Income | $12.1M | $12.1M | $18.4M | $-365000.00 | $-2.3M |
| EBITDA | $42.6M | $42.6M | $23.6M | $152000.00 | $-1.9M |
| EPS | 0.22 | 0.22 | 1.08 | -2.12 | -1.35 |
| Gross Margin | 17.3% | 17.3% | 21.6% | 100.0% | — |
| Operating Margin | 1.5% | 1.5% | 8.0% | 8.5% | — |
| Net Margin | 1.1% | 1.1% | 8.8% | -20.3% | — |
| Balance Sheet | |||||
| Debt/Equity | 0.25 | 0.25 | 0.02 | -2.15 | -1.70 |
| Cash Flow | |||||
| Free Cash Flow | $-927.3M | $-927.3M | $-78.4M | $-1.5M | $-1.8M |
| Returns | |||||
| ROE | 0.4% | 0.4% | 2.3% | 13.7% | 101.4% |
| Valuation | |||||
| P/E | 61.37 | 61.37 | 63.76 | — | — |
| EV/EBITDA | 42.25 | 42.25 | 49.74 | 44.29 | — |
| P/B | 0.59 | 0.59 | 1.44 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 427.6% | 427.6% | 11588.7% | — | — |
| EPS Growth | -79.6% | -79.6% | 150.9% | -56.8% | — |
| Dividend Yield | 0.0% | 0.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
144.4%
EPS terminal req.
$3.21
Spread vs growth
-224.1%
5Y implied EPS CAGR
77.6%
EPS terminal req.
$3.89
Spread vs growth
-157.2%
10Y implied EPS CAGR
39.8%
EPS terminal req.
$6.26
Spread vs growth
-119.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-56.1%
Start / end P/E
76.4x → 164.6x
EPS bridge
1.08 → 0.22
Residual
-91.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.